Role of Toll-Like Receptor Signaling in the Pathogenesis of Graft-versus-Host Diseases

por Tu, Sanfang, Zhong, Danli, Xie, Weixin, Huang, Wenfa, Jiang, Yangyang, Li, Yuhua
Publicado 2016

Current state of CAR-T therapy for T-cell malignancies

por Luo, Liangkui, Zhou, Xuan, Zhou, Lijuan, Liang, Zhao, Yang, Jilong, Tu, Sanfang, Li, Yuhua
Publicado 2022

Consolidative Hematopoietic Stem Cell Transplantation After CD19 CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: A Systematic Review and Meta-analysis

por Xu, Xinjie, Chen, Sifei, Zhao, Zijing, Xiao, Xinyi, Huang, Shengkang, Huo, Zhaochang, Li, Yuhua, Tu, Sanfang
Publicado 2021

Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies

por Xiao, Xinyi, Wang, Yazhuo, Zou, Zhengbang, Yang, Yufei, Wang, Xinyu, Xin, Xin, Tu, Sanfang, Li, Yuhua
Publicado 2022

A low-molecular-weight compound exerts anticancer activity against breast and lung cancers by disrupting EGFR/Eps8 complex formation

por Li, Meifang, Yang, Jilong, Zhang, Lenghe, Tu, Sanfang, Zhou, Xuan, Tan, Ze, Zhou, Weijun, He, Yanjie, Li, Yuhua
Publicado 2019

Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

por Nie, Yuru, Lu, Weiqing, Chen, Daiyu, Tu, Huilin, Guo, Zhenling, Zhou, Xuan, Li, Meifang, Tu, Sanfang, Li, Yuhua
Publicado 2020

Dual targeting of NUAK1 and ULK1 using the multitargeted inhibitor MRT68921 exerts potent antitumor activities

por Chen, Yiran, Xie, Xiaoling, Wang, Chunsheng, Hu, Yuxing, Zhang, Honghao, Zhang, Lenghe, Tu, Sanfang, He, Yanjie, Li, Yuhua
Publicado 2020

Design, synthesis, and biological evaluation of Bcr-Abl PROTACs to overcome T315I mutation

por Jiang, Liang, Wang, Yuting, Li, Qian, Tu, Zhengchao, Zhu, Sihua, Tu, Sanfang, Zhang, Zhang, Ding, Ke, Lu, Xiaoyun
Publicado 2021

Challenges and Clinical Strategies of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Overview and Developments

por Xu, Xinjie, Huang, Shengkang, Xiao, Xinyi, Sun, Qihang, Liang, Xiaoqian, Chen, Sifei, Zhao, Zijing, Huo, Zhaochang, Tu, Sanfang, Li, Yuhua
Publicado 2021

Preclinical and clinical advances in dual‐target chimeric antigen receptor therapy for hematological malignancies

por Guo, Zhenling, Tu, Sanfang, Yu, Siyao, Wu, Liufang, Pan, Wanying, Chang, Ning, Zhou, Xuan, Song, Chaoyang, Li, Yuhua, He, Yanjie
Publicado 2021

Mechanisms of Relapse After CD19 CAR T-Cell Therapy for Acute Lymphoblastic Leukemia and Its Prevention and Treatment Strategies

por Xu, Xinjie, Sun, Qihang, Liang, Xiaoqian, Chen, Zitong, Zhang, Xiaoli, Zhou, Xuan, Li, Meifang, Tu, Huilin, Liu, Yu, Tu, Sanfang, Li, Yuhua
Publicado 2019

EPS8 regulates proliferation, apoptosis and chemosensitivity in BCR-ABL positive cells via the BCR-ABL/PI3K/AKT/mTOR pathway

por Huang, Rui, Liu, Huimin, Chen, Yiran, He, Yanjie, Kang, Qian, Tu, Sanfang, He, Yingzhi, Zhou, Xuan, Wang, Lei, Yang, Jilong, Wu, Anqin, Li, Yuhua
Publicado 2018

CD19 and CD70 Dual-Target Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Relapsed and Refractory Primary Central Nervous System Diffuse Large B-Cell Lymphoma

por Tu, Sanfang, Zhou, Xuan, Guo, Zhenling, Huang, Rui, Yue, Chunyan, He, Yanjie, Li, Meifang, Chen, Yiran, Liu, YuChen, Chang, Lung-ji, Li, Yuhua
Publicado 2019

Busulfan plus fludarabine as a myeloablative conditioning regimen compared with busulfan plus cyclophosphamide for acute myeloid leukemia in first complete remission undergoing all...

por Liu, Hui, Zhai, Xiao, Song, Zhaoyang, Sun, Jing, Xiao, Yang, Nie, Danian, Zhang, Yu, Huang, Fen, Zhou, Hongsheng, Fan, Zhiping, Tu, Sanfang, Li, Yonghua, Guo, Xutao, Yu, Guopan, Liu, Qifa
Publicado 2013

Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study

por Xu, Dan, Yang, Ying, Yin, Zhao, Tu, Sanfang, Nie, Danian, Li, Yiqing, Huang, Zhenqian, Sun, Qixin, Huang, Changfen, Nie, Xiaqi, Yao, Zurong, Shi, Pengcheng, Zhang, Yu, Jiang, Xuejie, Liu, Qifa, Yu, Guopan
Publicado 2023

Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a...

por Xu, Xin, Fan, Zhiping, Wang, Yu, Huang, Fen, Xu, Yajing, Sun, Jing, Xu, Na, Deng, Lan, Li, Xudong, Liang, Xinquan, Luo, Xiaodan, Shi, Pengcheng, Liu, Hui, Chen, Yan, Tu, Sanfang, Huang, Xiaojun, Liu, Qifa, Xuan, Li
Publicado 2022

Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

por Zhou, Xuan, Tu, Sanfang, Wang, Chunsheng, Huang, Rui, Deng, Lan, Song, Chaoyang, Yue, Chunyan, He, Yanjie, Yang, Jilong, Liang, Zhao, Wu, Anqin, Li, Meifang, Zhou, Weijun, Du, Jingwen, Guo, Zhenling, Li, Yongqian, Jiao, Cheng, Liu, Yuchen, Chang, Lung-Ji, Li, Yuhua
Publicado 2020

Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, coh...

por Shao, Ruoyang, Zhang, Yu, He, Jinping, Huang, Fen, Fan, Zhiping, Yang, Kaibo, Xu, Yajing, Xu, Na, Luo, Yi, Deng, Lan, Zhang, Xi, Chen, Jia, Han, Mingzhe, Li, Xudong, Yu, Sijian, Liu, Hui, Liang, Xinquan, Luo, Xiaodan, Shi, Pengcheng, Wang, Zhixiang, Jiang, Ling, Zhou, Xuan, Lin, Ren, Chen, Yan, Tu, Sanfang, Sun, Jing, Wang, Yu, Liu, Qifa, Xuan, Li
Publicado 2023

2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma

por Li, Ping, Liu, Yang, Liang, Yun, Bo, Jian, Gao, Sujun, Hu, Yongxian, Hu, Yu, Huang, He, Huang, Xiaojun, Jing, Hongmei, Ke, Xiaoyan, Li, Jianyong, Li, Yuhua, Liu, Qifa, Lu, Peihua, Mei, Heng, Niu, Ting, Song, Yongping, Song, Yuqin, Su, Liping, Tu, Sanfang, Wang, Jianxiang, Wu, Depei, Wang, Zhao, Xu, Kailin, Ying, Zhitao, Yang, Qingming, Zhang, Yajing, Shi, Fengxia, Zhang, Bin, Zhang, Huilai, Zhang, Xi, Zhao, Mingfeng, Zhao, Weili, Zhao, Xiangyu, Huang, Liang, Zhu, Jun, Qian, Wenbin, Han, Weidong, Liang, Aibin
Publicado 2023